#United States #Tustin #Pangea Laboratory #John Moore #Bladder CARE

Pangea Laboratory Welcomes John Moore as Chief Executive Officer

Pangea Laboratory, renowned for its advanced cancer diagnostics and microbiome Next-Generation Sequencing (NGS) testing, has announced the appointment of John Moore as its new Chief Executive Officer. This decision comes as the organization seeks to strengthen its position in the rapidly evolving field of diagnostic testing.

Proven Leadership in Diagnostics

With a rich background spanning 25 years in commercial and operational leadership within the pharmaceutical and diagnostic laboratory sectors, John Moore is well-prepared to steer Pangea into its next chapter. His previous role as Chief Commercial Officer at HealthTrackRx exemplifies his successful leadership, where he played a pivotal part in scaling the laboratory to become a leader in PCR-based testing for infectious diseases. As he steps into his new position at Pangea, Moore plans to leverage the company’s technology to foster long-term growth and enhance its market leadership in high-impact, non-invasive precision diagnostics.

"What drew me to Pangea was the team's passion for transformative diagnostics that will bring more patients access to the right kind of care," Moore expressed. His enthusiasm suggests an exciting period ahead, as he aims to contribute to and build upon the innovative work already underway at the laboratory.

Innovative Solutions for Bladder Cancer

A particular focus for Pangea under Moore's leadership will be their groundbreaking Bladder CARE™ test. This non-invasive test is designed to facilitate early detection and ongoing monitoring of bladder cancer and Upper Tract Urothelial Carcinoma (UTUC), both of which represent significant challenges given their prevalence and high recurrence rates. Currently, routine diagnosis often involves invasive cystoscopy procedures, presenting a substantial burden for patients and healthcare systems.

The Bladder CARE™ test has been validated as a laboratory-developed test (LDT) and received Breakthrough Device designation from the FDA in December 2023. This recognition underlines its potential to revolutionize patient care by providing a safer, non-invasive diagnostic option. Mr. Moore emphasizes that the test is ready for clinical use in the United States, stating, "Bladder CARE™ is ready for clinical use within the United States and has the potential to change patients' lives for the better."

In addition to pursuing FDA 510(k) approval for broader recognition, Pangea is committed to developing robust strategies to improve patient access and reimbursement for this pioneering diagnostic.

Company Background and Future Outlook

Founded in 2014, Pangea Laboratory operates under CLIA certification and CAP accreditation and has been recognized for its expertise in next-generation sequencing (NGS), bioinformatics, and contract services. The company's mission underscores the importance of simplifying cancer diagnosis through early, sensitive, and non-invasive testing methods.

With transformative leadership from John Moore at the helm, Pangea Laboratory is poised to significantly impact the landscape of cancer diagnostics. As Dr. Larry Jia, the company’s Founder and President, noted, "We are entering an exciting new chapter at Pangea with John joining as CEO. His proven commercial leadership and ability to build high-performing teams will be instrumental in accelerating the growth of our innovative platforms in oncology, microbiomics, and beyond."

The future seems bright as Pangea Laboratory continues to innovate and lead in the diagnostic field, aiming for improved patient outcomes and enhanced accessibility to vital testing solutions.